Clinical trials including regorafenib, another multi-kinase inhibitor (B-RAF, receptor tyrosine kinases (e.g., VEGFR, PDGFR, KIT) with antitumoral effects in preclinical studies [12,13], showed that the SMI may contribute to a survival benefit in recurrent glioblastoma [14,15,16], while a small clinical study based on six patients had a less beneficial outcome [17]. This evidence concerns the gene NTRK1 and glioblastoma.